- Home
- OCS vs REPL Comparison
OCS vs REPL Comparison
Compare OCS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- REPL
- Stock Information
- Founded
- OCS 2003
- REPL 2015
- Country
- OCS Switzerland
- REPL United States
- Employees
- OCS N/A
- REPL N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- REPL Health Care
- Exchange
- OCS Nasdaq
- REPL Nasdaq
- Market Cap
- OCS 706.3M
- REPL 816.4M
- IPO Year
- OCS N/A
- REPL 2018
- Fundamental
- Price
- OCS $14.14
- REPL $10.80
- Analyst Decision
- OCS Strong Buy
- REPL Strong Buy
- Analyst Count
- OCS 5
- REPL 4
- Target Price
- OCS $29.20
- REPL $17.00
- AVG Volume (30 Days)
- OCS 73.4K
- REPL 432.6K
- Earning Date
- OCS 11-07-2024
- REPL 11-12-2024
- Dividend Yield
- OCS N/A
- REPL N/A
- EPS Growth
- OCS N/A
- REPL N/A
- EPS
- OCS N/A
- REPL N/A
- Revenue
- OCS $1,027,571.00
- REPL N/A
- Revenue This Year
- OCS $4.38
- REPL N/A
- Revenue Next Year
- OCS $905.09
- REPL $469.74
- P/E Ratio
- OCS N/A
- REPL N/A
- Revenue Growth
- OCS N/A
- REPL N/A
- 52 Week Low
- OCS $9.60
- REPL $4.92
- 52 Week High
- OCS $18.00
- REPL $12.97
- Technical
- Relative Strength Index (RSI)
- OCS 37.01
- REPL 38.50
- Support Level
- OCS $16.44
- REPL $11.45
- Resistance Level
- OCS $18.00
- REPL $12.73
- Average True Range (ATR)
- OCS 0.68
- REPL 0.69
- MACD
- OCS -0.46
- REPL -0.16
- Stochastic Oscillator
- OCS 3.50
- REPL 8.82
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.